Aromatic ring-substituted methoxy derivatives have been described in a Shanghai Yingli Pharmaceutical Co. Ltd. patent as potentially useful for the treatment of liver and stomach cancer.
The cyclic imine toxins represent a growing family of neurotoxic lipophilic compounds made by a variety of benthic marine dinoflagellate species. These cause many shellfish food poisonings worldwide. Their cyclic nature confers exceptional chemical stability with bioaccumulation, but the inability to synthesize adequate amounts of these molecules has precluded basic research of their mechanisms of action.
Researchers from Technische Universität München and Universitätsklinikum Augsburg recently presented the discovery of novel radiohybrid-based minigastrin analogues.
Beactica Therapeutics AB has entered into a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS). The collaboration will focus on the translation of novel proteolysis-targeting degraders of TEAD under development by Beactica for treatment of cancer.
Sygnature Discovery Ltd. and Ube Corp. have established a collaboration on a hit-to-lead program to identify SHP2 degraders. The aim is to develop potent bifunctional compounds with excellent ADME and pharmacokinetic properties for efficient degradation of SHP2, a tyrosine-specific phosphatase implicated in human cancers.
Mitochondria regulate many processes that are altered in cancer cells, from metabolism to oxidative stress to apoptosis. The metabolic reprogramming in cancer cells promotes an immunosuppressive environment that drives cancer progression. However, in a recent study, researchers from the Salk Institute of Biological Sciences have identified succinate as a metabolite that accumulated due to specific disturbances in the mitochondrial electron transport chain.
Wuhan Zhongcheng Health Bio-Pharm Technology Co. Ltd. has divulged naphthyridine derivatives acting as ATR kinase inhibitors reported to be useful for the treatment of cancer, psoriasis, keloids and benign prostatic hyperplasia.
Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has identified mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.
Debiopharm SA has entered into an exclusive option and license agreement with Sunrock Biopharma SL to advance the development of specifically targeted antibodies.
RSS
